Schweinfurthin Compounds With Checkpoint Inhibitors for Cancer Immunity
Solution Overview
Problem
Current treatments for melanoma, such as decarbazine chemotherapy and interleukin 2 immunotherapy, have modest success, leading to a 5-year survival rate of around 10% for advanced melanoma, necessitating more effective therapeutic options.
Innovation Solution
Combining schweinfurthin compounds with immune-checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 antibodies, to induce immunogenic cell death and enhance anti-cancer immune responses, thereby improving tumor control and survival rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If decarbazine chemotherapy or interleukin 2 immunotherapy is used to treat melanoma, then cancer cells are targeted and immune response is stimulated, but the treatment efficacy is limited resulting in only around 10% 5-year survival rate for advanced melanoma
Solution Approach 1:
The patent combines schweinfurthin compounds (which induce immunogenic cell death through calreticulin exposure) with immune-checkpoint inhibitors (such as anti-PD-1 or anti-PD-L1 antibodies) to create a synergistic therapeutic approach. This combination merges two distinct mechanisms: schweinfurthin-induced cell death that exposes tumor antigens, and checkpoint inhibition that releases immune suppression, resulting in enhanced anti-tumor immunity and improved survival rates compared to either treatment alone.
2Reliability
If schweinfurthin compounds are used alone to induce immunogenic cell death, then calreticulin is exposed on cell surface and immune response is triggered, but tumor regression is incomplete and survival benefit is limited
Solution Approach 1:
The patent uses immune-checkpoint inhibitors as intermediaries that bridge the gap between schweinfurthin-induced cell death and effective tumor regression. The checkpoint inhibitors mediate the enhancement of immune response by blocking inhibitory signals (PD-1/PD-L1 pathway), allowing T cells to fully recognize and eliminate tumor cells that have been primed by schweinfurthin treatment, thereby achieving complete tumor regression.
3Reliability
If immune-checkpoint inhibitors are used alone to block PD-1 or PD-L1 pathway, then immune suppression is relieved and T cell activity is enhanced, but anti-cancer effect is insufficient without adequate tumor antigen exposure
Solution Approach 1:
The patent applies schweinfurthin compounds as a preliminary action before or concurrent with immune-checkpoint inhibitor administration. The schweinfurthin treatment first induces immunogenic cell death, exposing tumor antigens and calreticulin on the cell surface, which primes the immune system. This preliminary antigen exposure creates the necessary conditions for the subsequent checkpoint inhibition to be highly effective, ensuring adequate tumor antigen presentation to T cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy results in enhanced anti-cancer immunity, delaying tumor progression, and in some cases, achieving complete tumor regression, with improved survival and reduced cancer recurrence.
Implementation Method 1
Schweinfurthin compounds such as TTI-4242 and TTI-3114 each efficiently induced plasma membrane surface localization of the ER-resident protein calreticulin in treated B16.F10 melanoma cells, indicative of the induction of immunogenic cell death.
Implementation Method 2
one or more schweinfurthin compounds and one or more immune-checkpoint inhibitors can be administered together to a mammal having cancer to treat the mammal
Data Source
AI summary
This document provides methods and materials for treating cancer. For example, methods and materials for using one or more schweinfurthin compounds and one or more immune-checkpoint inhibitors to treat a mammal having cancer are provided.